Newborn babies should be momtored carefully for the effects of theophylline, if Slo-Phyllin is taken during pregnancy. Slo-Phyllin should be used with caution in breast-feeding mothers, as theophylline is excreted in breast milk. If necessary, breast-feeding should take place immediately before administration of Slo-Phyllin and the infant should be carefully monitored for any effects of theophylline. If you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Omalizumab (Xolair) is FDA-approved for patients age 12 and older. It should be considered only for children over 12 years who have moderate-to-severe persistent asthma related to allergies and for adults who have severe asthma and allergies. The presence of allergies must generally be proven by increased levels in the blood of a certain antibody called IgE. The first drug of this type to be approved for asthma, omalizumab is a monoclonal antibody (MAb), a genetically developed drug designed to attack very specific targets. Omalizumab is given by injection every 2 - 4 weeks. It is used only to treat patients whose symptoms are not controlled by inhaled corticosteroids.